EyePoint Pharmaceuticals

Press Releases

pSivida To Present at the 30th Annual ROTH Conference
Mar 05, 2018
WATERTOWN, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the Company
pSivida to Present at the 2018 BIO CEO & Investor Conference
Feb 09, 2018
WATERTOWN, Mass. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the Company
pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
Feb 07, 2018
Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months       Awaiting FDA Decision to Accept NDA Submission for Review Conference Call and Webcast Today, February 7th , at 4:30 p.m.
pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
Feb 07, 2018
Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) --  pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Jan 24, 2018
Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th
pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
Jan 08, 2018
Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases
pSivida Granted Waiver by the FDA for New Drug Application Filing Fee
Jan 04, 2018
WATERTOWN, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, today announced that the U.S. Food and Drug Administration (FDA) granted its request for a small business waiver of the Prescription
pSivida to Present at the Annual Biotech Showcase Conference
Jan 02, 2018
WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, announced today that Nancy Lurker , President and Chief Executive Officer, will present at the Annual Biotech Showcase conference on
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
Dec 14, 2017
Sustained Release Technology Well Tolerated and Provides Pain Reduction
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
Nov 07, 2017
NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7th , at 8:30 a.m. ET WATERTOWN, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.
pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Oct 18, 2017
Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
Oct 10, 2017
Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds
pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
Sep 26, 2017
WATERTOWN, Mass. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has signed an agreement with a major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary
pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 22, 2017
WATERTOWN, Mass. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2017
pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
Sep 11, 2017
Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call and Webcast Today, September 11th , at 4:30 p.m. ET WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained
pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 11, 2017
WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual
pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
Sep 05, 2017
WATERTOWN, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report results for its fourth quarter and fiscal year ended June 30, 2017 on Monday,
pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
Aug 01, 2017
WATERTOWN, Mass. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker , President and Chief Executive Officer, will present at the
Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
Jul 18, 2017
WATERTOWN, Mass. , July 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that three abstracts supporting the Company's Durasert™ three-year treatment for posterior segment uveitis
pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida's Revenue Generation
Jul 10, 2017
WATERTOWN, Mass. , July 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences, Inc.
Displaying 21 - 40 of 316
EyePoint Pharmaceuticals